IL17A and Chronic mucocutaneous candidosis: Unlike most other MSMDs, a subset of patients with either of these two PIDs also carry susceptibility to chronic mucocutaneous candidiasis (CMC), thought to originate from compromised signaling via the IL-23/IL-17 pathway that is important for TH17 cell development and mucosal immunity52.